Karyopharm Therapeutics Inc. (KPTI) Stock Analysis
Verdict: AVOID
Severe debt distress and sub-10-month cash runway make KPTI a high-risk restructuring candidate despite temporary forbearance relief.
Investment score: 23/100
Analysis as of
Is Karyopharm Therapeutics Inc. stock worth reviewing? The TradeMates thesis
The TradeMates model assigns an AVOID recommendation to KPTI due to severe balance sheet distress, $233.6M in total debt, and a cash burn that leaves under 10 months of operational runway.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 15/100 (weight 10%)
- Analyst Consensus: 45/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Karyopharm Therapeutics Inc. opportunities and risks
What speaks for KPTI
- Debt Forbearance Extension
What speaks against KPTI
- Imminent Insolvency & Bankruptcy Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| KPTI | n/a | 0.1x | n/a | 95.9% | -153.3% | -346.2% |
| ATOS | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -151.3% |
| BYSI | n/a | 0.0x | n/a | 0.0% | 0.0% | -79.1% |
| KYNB | 0.1x | 4.1x | 0.3x | 18.2% | 3967.8% | -199.2% |
| NEUP | n/a | 15.5x | 0.1x | 43.5% | -1578.4% | -67943.9% |
| ACUT | n/a | 24.5x | n/a | 100.0% | -1680.0% | -50.0% |
| Peer median | n/a | 4.1x | 0.1x | 18.2% | 0.0% | -151.3% |
Frequently asked questions about Karyopharm Therapeutics Inc. (KPTI)
Is KPTI stock a good investment?
The TradeMates model rates Karyopharm Therapeutics Inc. as AVOID with an investment score of 23/100. The TradeMates model assigns an AVOID recommendation to KPTI due to severe balance sheet distress, $233.6M in total debt, and a cash burn that leaves under 10 months of operational runway. This is algorithmic model output, not personal investment advice.
Is KPTI stock a buy?
The TradeMates model verdict for KPTI is AVOID with an investment score of 23/100. Treat this as a model signal to review, not a personal buy recommendation.